Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

被引：5

作者：

Vinti, Luciana ^{[1
]}

Pagliara, Daria ^{[1
]}

Buffardi, Salvatore ^{[2
]}

Di Ruscio, Valentina ^{[1
]}

Stocchi, Francesca ^{[1
]}

Mariggio, Elena ^{[1
]}

Parasole, Rosanna ^{[2
]}

Di Matteo, Antonia ^{[2
]}

Petruzziello, Fara ^{[2
]}

Paganelli, Valeria ^{[1
]}

De Vito, Rita ^{[3
]}

Del Bufalo, Francesca ^{[1
]}

Strocchio, Luisa ^{[1
]}

Locatelli, Franco ^{[1
,4
]}

机构：

[1] IRCCS, Dept Paediat Haematol Oncol Cell & Gene Therapy, Bambino Gesu Childrens Hosp, Piazza S Onofrio 4, I-00165 Rome, Italy

[2] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematol Oncol, Naples, Italy

[3] IRCCS, Dept Pathol, Bambino Gesu Childrens Hosp, Rome, Italy

[4] Univ Rome, Dept Pediat, Sapienza, Rome, Italy

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 04期

关键词：

brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse; STEM-CELL TRANSPLANTATION; PHASE-II; CHILDREN; THERAPY; MULTICENTER; GEMCITABINE; VINORELBINE; RECURRENT; EFFICACY; CANCER;

D O I：

10.1002/pbc.29557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.

引用

页数：9

共 50 条

[21] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
Chen, Runzhe
Chen, Baoan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
[22] BRENTUXIMAB VEDOTIN-BENDAMUSTINE COMBINATION FOR HODGKIN LYMPHOMA: EXPERIMENT WITH 8 PATIENTS
Carola, C.
Dennetiere, S.
Votte, P.
Marolleau, J. P.
Royer, B.
HAEMATOLOGICA, 2016, 101 : 473 - 474
[23] Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
LaCasce, Ann S.
Bociek, Gregory
Sawas, Ahmed
Caimi, Paolo F.
Agura, Edward
Matous, Jeffrey
Ansell, Stephen
Crosswell, Howland
Islas-Ohlmayer, Miguel
Behler, Caroline
Cheung, Eric
Forero-Torres, Andres
Vose, Julie
O'Connor, Owen A.
Josephson, Neil
Advani, Ranjana
BLOOD, 2015, 126 (23)
[24] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Paydas, S.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, Z. A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Ferhanoglu, B.
ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
[25] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Siddiqi, Tanya
Thomas, Sandra H.
Chen, Robert
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85
[26] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S.
Bociek, R. Gregory
Sawas, Ahmed
Caimi, Paolo
Agura, Edward
Matous, Jeffrey
Ansell, Stephen M.
Crosswell, Howland E.
Islas-Ohlmayer, Miguel
Behler, Caroline
Cheung, Eric
Forero-Torres, Andres
Vose, Julie
O'Connor, Owen A.
Josephson, Neil
Wang, Yinghui
Advani, Ranjana
BLOOD, 2018, 132 (01) : 40 - 48
[27] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
A. Salihoglu
T. Elverdi
I. Karadogan
S. Paydas
E. Ozdemir
G. Erdem
N. Karadurmus
G. Akyol
L. Kaynar
ZA Yegin
G. Sucak
V. Ozkocaman
P. Topcuoglu
M. Ozcan
E. Birtas
H. Goker
Z. Baslar
B. Ferhanoglu
Annals of Hematology, 2015, 94 : 415 - 420
[28] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
Ferhanoglu, B.
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Paydas, S.
HAEMATOLOGICA, 2014, 99 : 675 - 676
[29] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Mei, Matthew
Tsai, Ni-Chun
Palmer, Joycelynne
Armenian, Saro
Chen, Robert
Rosen, Steven
Forman, Stephen
Popplewell, Leslie
Kwak, Larry
Martin, Peter
Maddocks, Kami
Bond, David
Herrera, Alex F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
[30] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
Massaro, Fulvio
Maerevoet, Marie
Meuleman, Nathalie
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250

← 1 2 3 4 5 →